Key facts
- Vesale Bioscience’s last known valuation is $11.3M (Jan 2026).
- It has raised $6.9M; the latest was Later Stage VC ($3.3M) in Jan 2026.
- Notable investors include Jerome Marjoie, Medical Forge.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Vesale Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Vesale Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vesale Bioscience
Developer of a health technology platform designed to provide research and development. The company's tool specializes in the research and development of systems and treatments using phage therapy for multiresistant infections, enabling patients to get treatment against infections caused by bacteria.
- Sector
- Healthcare
- HQ
- Ottignies-Louvain-la-Neuve, Belgium
- Founded
- 2018
- Employees
- 30
- Website
- phage.health/
- Ownership
- Privately Held (backing)
Vesale Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesale Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesale Bioscience in its N-PORT filings yet. We sweep new filings monthly.